PI3K inhibitors are finally coming of age
Abstract Overactive phosphoinositide 3-kinase (PI3K) in cancer and immune dysregulation
has spurred extensive efforts to develop therapeutic PI3K inhibitors. Although progress has …
has spurred extensive efforts to develop therapeutic PI3K inhibitors. Although progress has …
Targeting apoptosis in cancer therapy
BA Carneiro, WS El-Deiry - Nature reviews Clinical oncology, 2020 - nature.com
For over three decades, a mainstay and goal of clinical oncology has been the development
of therapies promoting the effective elimination of cancer cells by apoptosis. This …
of therapies promoting the effective elimination of cancer cells by apoptosis. This …
Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials
Z Niu, R Jin, Y Zhang, H Li - Signal Transduction and Targeted Therapy, 2022 - nature.com
Lung cancer is the leading cause of cancer-related death across the world. Unlike lung
adenocarcinoma, patients with lung squamous cell carcinoma (LSCC) have not benefitted …
adenocarcinoma, patients with lung squamous cell carcinoma (LSCC) have not benefitted …
Capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer: the PAKT trial
PURPOSE The phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway is frequently
activated in triple-negative breast cancer (TNBC). The AKT inhibitor capivasertib has shown …
activated in triple-negative breast cancer (TNBC). The AKT inhibitor capivasertib has shown …
[HTML][HTML] β-Sitosterol as a promising anticancer agent for chemoprevention and chemotherapy: mechanisms of action and future prospects
H Wang, Z Wang, Z Zhang, J Liu, L Hong - Advances in Nutrition, 2023 - Elsevier
Cancer is one of the primary causes of death worldwide, and its incidence continues to
increase yearly. Despite significant advances in research, the search for effective and …
increase yearly. Despite significant advances in research, the search for effective and …
A dual PI3K/HDAC inhibitor induces immunogenic ferroptosis to potentiate cancer immune checkpoint therapy
F Fan, P Liu, R Bao, J Chen, M Zhou, Z Mo, Y Ma, H Liu… - Cancer research, 2021 - AACR
The capacity of targeted anticancer agents to exert immunomodulatory effects provides a
strong rationale to develop novel agents suitable for combinatorial regimens with …
strong rationale to develop novel agents suitable for combinatorial regimens with …
PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting
LM Thorpe, H Yuzugullu, JJ Zhao - Nature Reviews Cancer, 2015 - nature.com
Abstract Phosphatidylinositol 3-kinases (PI3Ks) are crucial coordinators of intracellular
signalling in response to extracellular stimuli. Hyperactivation of PI3K signalling cascades is …
signalling in response to extracellular stimuli. Hyperactivation of PI3K signalling cascades is …
The PI3K/AKT/mTOR interactive pathway
T Ersahin, N Tuncbag, R Cetin-Atalay - Molecular BioSystems, 2015 - pubs.rsc.org
The phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of the rapamycin (mTOR)
signalling pathway is hyperactivated or altered in many cancer types and regulates a broad …
signalling pathway is hyperactivated or altered in many cancer types and regulates a broad …
The present and future of PI3K inhibitors for cancer therapy
Abstract Phosphoinositide 3-kinase (PI3K) signaling regulates cellular proliferation, survival
and metabolism, and its aberrant activation is one of the most frequent oncogenic events …
and metabolism, and its aberrant activation is one of the most frequent oncogenic events …
Targeting PI3K in cancer: impact on tumor cells, their protective stroma, angiogenesis, and immunotherapy
The PI3K pathway is hyperactivated in most cancers, yet the capacity of PI3K inhibitors to
induce tumor cell death is limited. The efficacy of PI3K inhibition can also derive from …
induce tumor cell death is limited. The efficacy of PI3K inhibition can also derive from …